{
  "abstract": "BackgroundInfection after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy develops over a changing clinical course. We examined two related questions: how completed Day+100 registry data characterize the infection-associated clinical phenotype, and whether information available by Day+14 can stratify subsequent infection risk through Day+100.MethodsWe analyzed 3,302 adults with large B-cell lymphoma using a 70:30 development/test partition. An all-history classifier used completed Day+100 records. The corrected Day+14 cohort included 2,876 patients with observation extending beyond the landmark; models used information available by Day+14. Supplemental outer cross-validation repeated development, and logistic recalibration used development cross-fitted scores. A separate common-feature model was evaluated in 465 pediatric and young-adult patients with B-cell acute lymphoblastic leukemia.ResultsInfection was recorded in 735/3,302 adults (22.3%). The all-history test AUROC was 0.724 (95% CI, 0.685–0.765). In the corrected Day+14 test set (862 patients; 113 infections), the dynamic-model AUROC was 0.669 (95% CI, 0.616–0.716) and AUPRC was 0.217 (95% CI, 0.165–0.286). At score cutoff 0.25, the low-score group contained 160/862 patients (18.6%) and 5 infections (3.1%; 95% CI, 1.0–7.1%). Its raw and recalibrated Brier scores were 0.198 and 0.110, compared with 0.114 for the development-prevalence reference. In the cross-disease evaluation, the common-feature model achieved an AUROC of 0.663.ConclusionsCompleted records characterize infection-associated clinical trajectories. Day+14 information identifies a low-score subgroup for prospective evaluation of outpatient monitoring, with its coverage, event rate and calibration defining the conditions for that evaluation.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hematology, The First People’s Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Yunnan Province Clinical Research Center for Hematologic Disease, Kunming, China",
    "Yunnan Provincial Clinical Medical Center for Blood Diseases and Thrombosis Prevention and Treatment, The First People’s Hospital of Yunnan Province, Kunming, China",
    "Yunnan Atherosclerosis Cooperation Base of Chinese and Western Medicine, The First People’s Hospital of Yunnan Province, Kunming, China",
    "The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Yunnan, China",
    "The Second Affiliated Hospital of Kunming Medical University, Yunnan, China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 26,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Liuyang Yang"
    },
    {
      "affs": [
        1
      ],
      "name": "Liuyang Yang"
    },
    {
      "affs": [
        2
      ],
      "name": "Liuyang Yang"
    },
    {
      "affs": [
        3
      ],
      "name": "Liyu Shan"
    },
    {
      "affs": [
        4
      ],
      "name": "Liyu Shan"
    },
    {
      "affs": [
        0
      ],
      "name": "Shuai Feng"
    },
    {
      "affs": [
        1
      ],
      "name": "Shuai Feng"
    },
    {
      "affs": [
        2
      ],
      "name": "Shuai Feng"
    },
    {
      "affs": [
        0
      ],
      "name": "Renbin Zhao"
    },
    {
      "affs": [
        1
      ],
      "name": "Renbin Zhao"
    },
    {
      "affs": [
        2
      ],
      "name": "Renbin Zhao"
    },
    {
      "affs": [
        0
      ],
      "name": "Yan Wen"
    },
    {
      "affs": [
        1
      ],
      "name": "Yan Wen"
    },
    {
      "affs": [
        2
      ],
      "name": "Yan Wen"
    },
    {
      "affs": [
        0
      ],
      "name": "Xuezhong Gu"
    },
    {
      "affs": [
        1
      ],
      "name": "Xuezhong Gu"
    },
    {
      "affs": [
        2
      ],
      "name": "Xuezhong Gu"
    },
    {
      "affs": [
        0
      ],
      "name": "Zengzheng Li"
    },
    {
      "affs": [
        1
      ],
      "name": "Zengzheng Li"
    },
    {
      "affs": [
        2
      ],
      "name": "Zengzheng Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiangmei Yao"
    },
    {
      "affs": [
        1
      ],
      "name": "Xiangmei Yao"
    },
    {
      "affs": [
        2
      ],
      "name": "Xiangmei Yao"
    },
    {
      "affs": [
        0
      ],
      "name": "Yajie Wang"
    },
    {
      "affs": [
        1
      ],
      "name": "Yajie Wang"
    },
    {
      "affs": [
        2
      ],
      "name": "Yajie Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2c89cnmzxz37h.bib",
  "cited_by": 0,
  "doi": "10.3389/fcimb.2026.1933555",
  "fulltext_url": "https://www.frontiersin.org/articles/10.3389/fcimb.2026.1933555/full",
  "id": "2c89cnmzxz37h",
  "issns": [
    "2235-2988"
  ],
  "landing_url": "https://doi.org/10.3389/fcimb.2026.1933555",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "QR1-502"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7223373955",
  "pdf_url": "https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2026.1933555/pdf",
  "pmcid": "PMC13739542",
  "pmid": "42996212",
  "published": "2026-10-23",
  "publisher": "Frontiers Media S.A.",
  "ris": "https://research.draconitic.com/paper/2c89cnmzxz37h.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T13:43:11Z",
      "native_id": "621c8746c2b24adb82e77ec2305d1c56",
      "source": "doaj",
      "url": "https://doi.org/10.3389/fcimb.2026.1933555"
    },
    {
      "first_seen": "2026-11-09T15:20:41Z",
      "native_id": "MED:42996212",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42996212"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "Temporal clinical trajectories and Day+14 landmark stratification of infection risk after CD19 CAR T-cell therapy",
  "title_text": "Temporal clinical trajectories and Day+14 landmark stratification of infection risk after CD19 CAR T-cell therapy",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T15:20:41Z",
  "url": "https://research.draconitic.com/paper/2c89cnmzxz37h",
  "venue": "Frontiers in Cellular and Infection Microbiology",
  "versions": []
}